Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 06, 2015; 84 (14 Supplement) April 22, 2015

Resveratrol is safe and well-tolerated in individuals with mild-moderate dementia due to Alzheimer’s disease. (S33.009)

R Turner, Ronald Thomas, Suzanne Craft, Christopher van Dyck, Jacobo Mintzer, Brigid Reynolds, James Brewer, Robert Rissman, Rema Raman, Paul Aisen
First published April 8, 2015,
R Turner
2Neurology Georgetown University Washington DC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald Thomas
1La Jolla CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suzanne Craft
6Geriatric Medicine Wake Forest University Winston-Salem NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher van Dyck
7Yale Univ. New Haven CT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacobo Mintzer
3Medical University of South Carolina United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brigid Reynolds
2Neurology Georgetown University Washington DC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Brewer
5University of California, San Diego La Jolla CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Rissman
5University of California, San Diego La Jolla CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rema Raman
1La Jolla CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Aisen
4UCSD La Jolla CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Resveratrol is safe and well-tolerated in individuals with mild-moderate dementia due to Alzheimer’s disease. (S33.009)
R Turner, Ronald Thomas, Suzanne Craft, Christopher van Dyck, Jacobo Mintzer, Brigid Reynolds, James Brewer, Robert Rissman, Rema Raman, Paul Aisen
Neurology Apr 2015, 84 (14 Supplement) S33.009;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective. A phase 2 randomized, placebo-controlled, double-blind, multicenter 12-month trial of resveratrol in individuals with mild-moderate AD. We examined safety and tolerability, and change in volumetric MRI, plasma Aβ40 and Aβ42, and CSF Aβ40, Aβ42, tau, and phosphoTau181, and clinical outcomes. Background. Similar to caloric restriction, resveratrol treatment reduces cognitive decline and neuropathology in animal models of AD - perhaps via activation of sirtuins and promotion of autophagy. Methods. Subjects (N=119) were randomized (1:1) to placebo or resveratrol 500 mg by mouth once daily (dose escalation by 500 mg every 13 weeks, ending with 1000 mg twice daily). A total of 104 subjects completed the study (12.6[percnt] dropout). Brain MRIs and CSF collections were performed at baseline and week 52. After randomization there were no differences between groups (including AD severity) with the exception of a longer disease duration in the placebo group compared to the treatment group (5.5 +/- 2.6 versus 3.9 +/- 2.3 years, mean +/- SD, p < 0.001). The primary efficacy analyses were based on intent to treat. Results. Gastrointestinal symptoms were the most common drug-related adverse events. Resveratrol and its major metabolites were measurable in plasma and CSF (with 3[percnt] BBB penetration of native resveratrol). CSF Aβ40 levels declined 14[percnt] in the placebo group and 1[percnt] in the resveratrol group, resulting in a significant difference in mean change at week 52 (p = 0.002). A similar pattern was found with plasma Aβ40 (p = 0.024). No significant differences were found with CSF and plasma Aβ42, and CSF tau and phosphoTau181. Brain volume declined 3[percnt] in the treatment group and 1[percnt] in the placebo group (p = 0.03). Conclusions. Resveratrol is safe and well-tolerated in individuals with mild-moderate AD. Further studies are needed to interpret these biomarker changes. (NIA U01 AG010483; ClinicalTrials.gov NCT01504854; FDA IND 104205).

Disclosure: Dr. Turner has received personal compensation for activities with Pfizer Inc., Wyeth Pharmaceuticals, Janssen Pharmaceutica, Eli Lilly & Company, Baxter, and Ceregene as a consultant. Dr. Thomas has received personal compensation for activities with Medivation and Myriad Genetics. Dr. Craft has nothing to disclose. Dr. van Dyck has received personal compensation for activities with Yale University School of Medicine as employee. Dr. van Dyck has received personal compensation for activities with Pfizer Inc., Novartis, Janssen Pharmaceutica, and Forest Laboratories a Dr. Mintzer has nothing to disclose. Dr. Reynolds has nothing to disclose. Dr. Brewer has received personal compensation for activities with Eli Lilly & Company. Dr. Brewer holds stock and/or stock options in CorTechs Laboratories. Dr. Brewer has received research support from Janssen. Dr. Rissman has nothing to disclose. Dr. Raman has nothing to disclose. Dr. Aisen has received personal compensation for activities with Neurochem, Pfizer, Merck, Roche, Amgen, Medivation, Pamlab, Adlyfe, Eisai, GlaxoSmithKline, Eli Lilly, Daiichi, Elan, Wyeth, Avid, Novartis, and Martek as a consultant.

Wednesday, April 22 2015, 4:00 pm-5:45 pm

  • Copyright © 2015 by AAN Enterprises, Inc.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Safety and Efficacy of Tenecteplase and Alteplase in Patients With Tandem Lesion Stroke: A Post Hoc Analysis of the EXTEND-IA TNK Trials

Dr. Nicole Sur and Dr. Mausaminben Hathidara

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (22)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise